NASDAQ:MTCR Metacrine - MTCR News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Metacrine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.53 +0.03 (+6.18%) (As of 01/31/2023 05:19 PM ET) Add Compare Share Share Today's Range$0.51▼$0.5350-Day Range$0.35▼$0.5052-Week Range$0.30▼$0.68Volume721,312 shsAverage Volume358,261 shsMarket Capitalization$22.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Metacrine News Delivered to You Automatically Sign up to receive the latest news and ratings for MTCR and its competitors with MarketBeat's FREE daily newsletter. Email Address MTCR Media Mentions By Week MTCR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTCR News Sentiment▼0.160.72▲Average Medical News Sentiment MTCR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTCR Articles This Week▼60▲MTCR Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMetacrine, Inc. (NASDAQ:MTCR) Insider Michael York Sells 107,054 Sharesamericanbankingnews.com - January 28 at 7:19 AMPreston Klassen Sells 380,605 Shares of Metacrine, Inc. (NASDAQ:MTCR) Stockamericanbankingnews.com - January 28 at 6:32 AMMetacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreementfinance.yahoo.com - December 23 at 7:51 PMMetacrine, Inc.: Metacrine Reports Third-Quarter 2022 Resultsfinanznachrichten.de - November 17 at 6:47 AMMetacrine Reports Third-Quarter 2022 Resultsfinance.yahoo.com - November 15 at 11:05 AMEquillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis - Yahoo Financefinance.yahoo.com - September 28 at 7:39 PMLifshitz Law PLLC Announces Investigations of TALO, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equilli - Benzingabenzinga.com - September 25 at 12:13 AMLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equilli - Benzingabenzinga.com - September 22 at 6:52 AMLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - MarketWatchmarketwatch.com - September 21 at 8:52 PMLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equillium (NASDAQ:EQ) - Benzingabenzinga.com - September 17 at 7:53 PMMETACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCRbenzinga.com - September 8 at 12:38 PMSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates STR, MNRL, EQ, MTCR - GlobeNewswireglobenewswire.com - September 7 at 10:11 AMApexigen, Inc. - Common Stock (APGN), (AQST), (ATIP), (ATXI), Cardiff Oncology, Inc. - Common Stock (CRDF - Benzingabenzinga.com - September 7 at 12:07 AMEquillium to Acquire Metacrine in All-Stock Transaction - Yahoo Financefinance.yahoo.com - September 7 at 12:07 AMEquillium acquires Metacrine to extend cash runway through 2024 (NASDAQ:MTCR) - Seeking Alphaseekingalpha.com - September 7 at 12:07 AMMTCR Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Metacrine Inc. Is Fair to Shareholderstechnews.tmcnet.com - September 6 at 7:07 PMMetacrine, Inc. (MTCR)finance.yahoo.com - September 5 at 10:19 PMMetacrine: Q2 Earnings Insights - Benzingabenzinga.com - August 10 at 4:16 AMMetacrine Reports Second-Quarter 2022 Results - Benzingabenzinga.com - August 9 at 11:15 PMMetacrine Reports Second-Quarter 2022 Resultsfinance.yahoo.com - August 9 at 5:55 PMWhy did Arrowhead Pharmaceuticals stock pop up today? - Seeking Alphaseekingalpha.com - June 29 at 5:17 PMForte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President - Yahoo Financefinance.yahoo.com - June 7 at 11:18 AMMetacrine shares are trading higher after the company reported Q1 earnings results. - Benzinga - Benzingabenzinga.com - May 13 at 1:28 AMMetacrine Reports First-Quarter 2022 Results - Yahoo Financefinance.yahoo.com - May 13 at 1:28 AMMetacrine Reports First-Quarter 2022 Resultsfinance.yahoo.com - May 13 at 1:28 AMMetacrine Reports Fourth-Quarter 2021 Results - Benzinga - Benzingabenzinga.com - March 31 at 8:04 PMMetacrine Reports Fourth-Quarter 2021 Results - GlobeNewswireglobenewswire.com - March 31 at 3:05 AMMetacrine Reports Fourth-Quarter 2021 Resultsfinance.yahoo.com - March 30 at 10:04 PMMetacrine Announces Executive Leadership Changes - StreetInsider.comstreetinsider.com - February 25 at 5:28 AMMetacrine CFO steps down - Seeking Alphaseekingalpha.com - February 25 at 12:27 AMMetacrine Announces Executive Leadership Changesfinance.yahoo.com - February 24 at 7:26 PMMetacrine Reports It Remains On Track To Begin Phase 2 Trial In Ulcerative Colitis - Benzingabenzinga.com - February 13 at 4:03 AMMetacrine To Slash Its Workforce By 50%finance.yahoo.com - February 11 at 4:39 PMMetacrine Updates IBD Clinical Development Strategy and Implements Restructuring Planfinance.yahoo.com - February 11 at 11:38 AMMetacrine Inc Shares Approach 52-Week Low - Market Mover - Nasdaqnasdaq.com - January 8 at 6:30 AMDr. Hubert Chen Joins ADARx Pharmaceuticals as Chief Medical Officer - StreetInsider.comstreetinsider.com - January 7 at 8:33 AMMetacrine Inc Shares Approach 52-Week Low - Market Movernasdaq.com - December 30 at 8:33 AMUPDATE: Jefferies Assumes Metacrine Inc. (MTCR) at Hold - StreetInsider.comstreetinsider.com - December 29 at 8:19 AMMetacrine shares are trading lower after the company announced the resignation of the Chief Medical Officer. - Benzingabenzinga.com - December 27 at 7:05 PMMetacrine Announces Resignation of Chief Medical Officer - GlobeNewswireglobenewswire.com - December 27 at 8:46 AMMetacrine Inc Shares Close in on 52-Week Low - Market Mover - Nasdaqnasdaq.com - December 26 at 6:09 PMTPG Pace Beneficial II Corp - Class A Shares Near 52-Week Low - Market Mover - Nasdaqnasdaq.com - December 26 at 1:08 PMMetacrine Inc Shares Near 52-Week Low - Market Mover - Nasdaqnasdaq.com - December 25 at 8:38 PMFrontier Investment Corp - Class A Shares Near 52-Week Low - Market Mover - Nasdaqnasdaq.com - December 24 at 7:39 AMMetacrine Inc Shares Fall 8.3% Below Previous 52-Week Low - Market Mover - Nasdaqnasdaq.com - December 24 at 12:16 AM4 Solid Retail Stocks to Buy in a Challenging Industry - Yahoo Financefinance.yahoo.com - December 20 at 3:57 PMIs the Options Market Predicting a Spike in Metacrine (MTCR) Stock? - Nasdaqnasdaq.com - December 20 at 10:55 AMIs the Options Market Predicting a Spike in Metacrine (MTCR) Stock?finance.yahoo.com - December 20 at 10:55 AMForm 10-Q Metacrine, Inc. For: Sep 30 - StreetInsider.comstreetinsider.com - November 12 at 5:35 PMMetacrine Reports Third-Quarter 2021 Results - Yahoo Financefinance.yahoo.com - November 12 at 12:34 PM Get Metacrine News Delivered to You Automatically Sign up to receive the latest news and ratings for MTCR and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:MTCR) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.